image
Healthcare - Biotechnology - NASDAQ - US
$ 13.45
0.298 %
$ 546 M
Market Cap
-79.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one KROS stock under the worst case scenario is HIDDEN Compared to the current market price of 13.4 USD, Keros Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one KROS stock under the base case scenario is HIDDEN Compared to the current market price of 13.4 USD, Keros Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one KROS stock under the best case scenario is HIDDEN Compared to the current market price of 13.4 USD, Keros Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart KROS

image
$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
3.55 M REVENUE
2250.99%
-211 M OPERATING INCOME
-24.06%
-187 M NET INCOME
-22.46%
-161 M OPERATING CASH FLOW
-29.20%
-1.93 M INVESTING CASH FLOW
21.63%
392 M FINANCING CASH FLOW
118.95%
211 M REVENUE
6844.31%
152 M OPERATING INCOME
385.50%
148 M NET INCOME
422.54%
161 M OPERATING CASH FLOW
450.31%
-565 K INVESTING CASH FLOW
-95.50%
4 K FINANCING CASH FLOW
-99.99%
Balance Sheet Keros Therapeutics, Inc.
image
Current Assets 589 M
Cash & Short-Term Investments 560 M
Receivables 4.46 M
Other Current Assets 24.5 M
Non-Current Assets 27 M
Long-Term Investments 0
PP&E 23.5 M
Other Non-Current Assets 3.5 M
90.91 %3.98 %3.81 %Total Assets$615.9m
Current Liabilities 27.4 M
Accounts Payable 4.6 M
Short-Term Debt 1.98 M
Other Current Liabilities 20.9 M
Non-Current Liabilities 16.9 M
Long-Term Debt 16.9 M
Other Non-Current Liabilities 0
10.38 %4.46 %47.08 %38.08 %Total Liabilities$44.3m
EFFICIENCY
Earnings Waterfall Keros Therapeutics, Inc.
image
Revenue 3.55 M
Cost Of Revenue 0
Gross Profit 2.32 M
Operating Expenses 214 M
Operating Income -211 M
Other Expenses -23.5 M
Net Income -187 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)4m02m(214m)(211m)23m(187m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
65.38% GROSS MARGIN
65.38%
-5938.96% OPERATING MARGIN
-5938.96%
-5277.55% NET MARGIN
-5277.55%
-32.78% ROE
-32.78%
-30.42% ROA
-30.42%
-35.77% ROIC
-35.77%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Keros Therapeutics, Inc.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)20192019202020202021202120222022202320232024202420252025
Net Income -187 M
Depreciation & Amortization 1.23 M
Capital Expenditures -1.93 M
Stock-Based Compensation 34.9 M
Change in Working Capital -11.4 M
Others -6.77 M
Free Cash Flow -163 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Keros Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for KROS of $101 , with forecasts ranging from a low of $96 to a high of $107 .
KROS Lowest Price Target Wall Street Target
96 USD 613.75%
KROS Average Price Target Wall Street Target
101 USD 650.93%
KROS Highest Price Target Wall Street Target
107 USD 695.54%
Price
Max Price Target
Min Price Target
Average Price Target
11011010010090908080707060605050404030302020101000Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Keros Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
22 M USD 2
Bought
9.46 M USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy AUSTIN, Texas , June 9, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company"), today issued the following statement regarding the results of the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"): "We believe the outcome of the Annual Meeting underscores what we have consistently conveyed to Keros' Board of Directors: there is broad and growing concern among stockholders regarding the Board's capital allocation decisions and fidelity to stockholder interests. ADAR1 previously disclosed its intention to withhold votes from Dr. Mary Ann Gray and Dr. Alpna Seth at the Annual Meeting. prnewswire.com - 4 weeks ago
Keros Announces Return of $375 Million in Excess Capital to Stockholders Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 globenewswire.com - 1 month ago
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 a.m. Eastern time. globenewswire.com - 1 month ago
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill. In the presentation titled, “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and. businesswire.com - 1 month ago
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced topline data from the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (“PAH”), and provided a corporate update. globenewswire.com - 1 month ago
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees Keros Board Best Equipped to Oversee Strategic Review Process and  Execute on Ultimate Outcome of that Process globenewswire.com - 1 month ago
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual Meeting AUSTIN, Texas , May 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that Keros stockholders WITHHOLD votes from incumbent directors Dr. Mary Ann Gray and Dr. Alpna Seth at the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting"), scheduled for June 4, 2025. In its report, ISS raised serious concerns regarding the Company's governance and concluded that greater accountability at Keros is needed. prnewswire.com - 1 month ago
ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth AUSTIN, Texas , May 12, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an investor presentation outlining its rationale for withholding votes on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Keros Board of Directors at the Company's upcoming Annual Meeting of Stockholders, scheduled for June 4, 2025. The presentation can be viewed here. prnewswire.com - 1 month ago
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. globenewswire.com - 1 month ago
Keros Reinforces Commitment to Maximizing Stockholder Value Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company's  Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today issued the following statement in response to the misleading press release issued by ADAR1 Capital Management (“ADAR1”) regarding Keros' upcoming 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”), currently scheduled for June 4, 2025: The Board is committed to acting in the best interests of the Company and all of its stockholders. globenewswire.com - 2 months ago
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth AUSTIN, Texas , May 8, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released a public letter to fellow Keros stockholders outlining its concerns with the Company's capital allocation decisions, strategic direction, and prolonged underperformance. In the letter, ADAR1 details the Company's alarming clinical results for two of its three drug candidates — KER-012 and KER-065 — and expresses serious concern that continued investment in these programs risks further shareholder value destruction. prnewswire.com - 2 months ago
8. Profile Summary

Keros Therapeutics, Inc. KROS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 546 M
Dividend Yield 0.00%
Description Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Contact 99 Hayden Avenue, Lexington, MA, 02421 https://www.kerostx.com
IPO Date April 8, 2020
Employees 163
Officers Mr. Keith C. Regnante MBA Chief Financial Officer Dr. Yung H. Chyung M.D. Chief Medical Officer Ms. Robin Wagner Senior Vice President of Human Resources Mr. John Oram M.B.A. Senior Vice President of Program & Portfolio Management Dr. Jasbir S. Seehra Ph.D. Chief Executive Officer & Chair of the Board Mr. Christopher Rovaldi M.Sc. President & Chief Operating Officer Ms. Esther Cho J.D. Senior Vice President, General Counsel & Secretary